Tixagevimab and Cilgavimab

Kathryn Dzintars, Pharm.D., BCPS
Tixagevimab and Cilgavimab is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) permitting the emergency use of tixagevimab/cilgavimab for pre-exposure (PrEP) of COVID-19 in adults and pediatric patients (≥12 years of age and at least 40kg) who are not currently infected with SARS-CoV-2, have not had recent exposure to SARS-CoV-2.

AND

  • Have moderate to severe immune-compromised status due to a medical condition or immunosuppressive medications/treatment and may not mount an adequate immune response from COVID-19 vaccination

OR

  • For whom vaccination with any available COVID-19 vaccine, according to the approved/authorized schedule, is not recommended due to a history of severe adverse reaction (e.g. severe allergic reaction) to a COVID-19 vaccine and/or vaccine component

Tixagevimab/cilgavimab is NOT indicated for:

  • The treatment of COVID-19 disease
  • Post-exposure (PEP) of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2

PrEP is not a substitute for vaccination in individuals for whom vaccination is recommended. For individuals who have been vaccinated, tixagevimab/cilgavimab should be administered 2 weeks after vaccine administration.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) permitting the emergency use of tixagevimab/cilgavimab for pre-exposure (PrEP) of COVID-19 in adults and pediatric patients (≥12 years of age and at least 40kg) who are not currently infected with SARS-CoV-2, have not had recent exposure to SARS-CoV-2.

AND

  • Have moderate to severe immune-compromised status due to a medical condition or immunosuppressive medications/treatment and may not mount an adequate immune response from COVID-19 vaccination

OR

  • For whom vaccination with any available COVID-19 vaccine, according to the approved/authorized schedule, is not recommended due to a history of severe adverse reaction (e.g. severe allergic reaction) to a COVID-19 vaccine and/or vaccine component

Tixagevimab/cilgavimab is NOT indicated for:

  • The treatment of COVID-19 disease
  • Post-exposure (PEP) of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2

PrEP is not a substitute for vaccination in individuals for whom vaccination is recommended. For individuals who have been vaccinated, tixagevimab/cilgavimab should be administered 2 weeks after vaccine administration.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: March 17, 2022